Abstract
Rituximab is a monoclonal antibody which targets CD20 in B cells that is used for the treatment of CD20 positive oncologic and hematologic malignancies. Rituximab causes hypersensitivity reactions during infusions. The delay of treatment or loss of a highly efficient drug can be prevented by rapid drug desensitization method in patients who are allergic to rituximab. We report a low grade B cell non-Hodgkin lymphoma patient with rituximab hypersensitivity successfully treated with rapid drug desensitization. In experienced centers, drug desensitization is a novel modality to break through in case of hypersensitivity that should be considered.
Highlights
Monoclonal antibody research has entered a new era in targeting of specific proteins associated with disease pathogenesis [1]
5.625 (1–8: 5.902) 750–5.902: 744 mg will be given in steps we present a patient with non-Hodgkin’s lymphoma (NHL) who was treated successfully with rituximab in our center despite having a history of severe rituximab related adverse reaction
Clinical manifestations of IgE-related and non-IgE related infusion reactions overlap; rash, hypotension, nausea, tachycardia, and shortness of breath have been described in both reactions [3]
Summary
Monoclonal antibody research has entered a new era in targeting of specific proteins associated with disease pathogenesis [1]. Hypersensitivity reactions to monoclonal antibodies limit their practicality [2]; these reactions have been reported following initial or repeated exposures [1]. Most of these reactions involve nonimmune cytokine releases that occur during the intravenous administration of the agent. Desensitization is a treatment method that enables patients, who have previously experienced hypersensitivity reactions, to be treated with the culprit drug [1]. 5.625 (1–8: 5.902) 750–5.902: 744 mg will be given in steps we present a patient with NHL who was treated successfully with rituximab in our center despite having a history of severe rituximab related adverse reaction
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
